Effect of zoledronic acid on primary osteoporosis in the treatment of bone pain and bone mineral density
Objective To investigate the efficacy of zoledronic acid in patients with primary osteoporosis. Methods We retrospectively analyzed the diagnosis and treatment of 160 patients with primary osteoporosis in the hospital from February 2016 to May 2017. The patients were treated with oral calcium Erqi D and alendronate as the control group, and treated with zoledronic acid and oral calcium as observation group. The lumbar spine (L1-3) and hip bone mineral density were measured before and after treatment. Results the adverse reactions during treatment. Results The bone density of lumbar vertebrae (L1-3) and hip was significantly higher than that of the control group (P<0.05). The pain score of the two groups was significantly lower than that of the before treatment (P<0.05). The bone density of the lumbar vertebrae (L1-3) and the hip bone were significantly higher than those in the control group (P<0.05). The differences of adverse reactionsbetween two groups was not significant. Conclusion The use of zoledronic acid in the treatment of primary osteoporosis may be beneficial to improve its bone density, relieve its pain, and has a certain safety.
bone densityzoledronic acidprimary osteoporosiscalcium Erqi Dalendronate sodium
NETL
NSTL
万方数据
维普
